• Examine the time between regulatory approval and launch/pricing and reimbursement (P&R) approval in the EU5 and US -Illustrate any differences between general medicines, oncology and orphan drugs within and across the countries • New molecular entities, formulations and combinations approved by the EMA (EC centralized approval) between January 2009 and May 2014 were included in the analysis. FDA approval dates were retrieved.
• Examine the time between regulatory approval and launch/pricing and reimbursement (P&R) approval in the EU5 and US -Illustrate any differences between general medicines, oncology and orphan drugs within and across the countries -Look for changes in these timelines over a 5 year period (January 2009 to May 2014 -Additional analysis of trends for products launched between April 2013 and May 2014
• New molecular entities, formulations and combinations approved by the EMA (EC centralized approval) between January 2009 and May 2014 were included in the analysis. FDA approval dates were retrieved.
• Time comparison for general medicines vs. orphan and oncology indications was made including shifts over time
• Drugs with time to market >1000 days were considered outliers and removed from the analysis
• Timing differences were NOT weighted by the number of products not available by country and category
OBJECTIVES & METHODS
• Increasing divergence between regulatory and P&R approval and a dearth of literature on time to market access in recent times makes this topic both a relevant and interesting issue for analysis -Average time from FDA approval to US launch was 6 weeks (oncology 4 weeks; orphan drugs 2 weeks) which is much faster than all EU5 countries -Although time to market in the UK appears short (20 weeks), HTA assessments often mean significant access delays -~85% of all EMA approved medications in this time period were available in Germany, whereas only 45% had completed P&R negotiations in France § 60% of medications that had completed P&R in France were available across the EU5 and 91% were available in at least 3 of the other markets (in most cases the medication had not completed P&R in Spain but was available in Italy, Germany and the UK)
-Spain has the poorest access for orphan drugs; only 24% of orphan medications approved by the EMA in this time period had completed P&R negotiations as of May 2014 
RESULTS
• Average time to market in the US is considerably shorter than in the EU5 countries
• Wide disparity exists in the number of EMA approved medications available in each of the EU5 countries and the time to market -While ~85% of all medications approved by the EMA are available in Germany, only 45% have completed P&R negotiation in France -Dramatic access issues for orphan drugs in Spain are highlighted by the fact that patients only have access to a quarter of medications approved by the EMA -In the EU5, the German and UK launches on average were within 4 to 6 months of authorization, while France, Italy and Spain are >1 year -Although time to P&R post-regulatory approval has stayed the same in most countries, it has increased by ~6 weeks in Italy and ~25 weeks in Spain for products launched in the latest year vs. those launched previously • It is important to recognize variation in ability to launch and timing disparities when analysing market access timelines and their implications on the availability of new drugs to patients 
CONCLUSIONS

